Krystal Biotech, Inc. KRYS Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | 41.4%+18.8pp | 22.6%+245pp | -222.6%— | —— | |
| Net margin | 52.6%+21.9pp | 30.7%+9.1pp | 21.6%— | —— | |
| Returns | |||||
| Return on equity | 18.9%+8.6pp | 10.3%+8.7pp | 1.7%+26.8pp | -25.1%-9.4pp | |
| Return on invested capital | 24%+12.2pp | 11.9%+40.1pp | -28.3%+17.8pp | -46.1%+1.3pp | |
| Efficiency | |||||
| Asset turnover | 0.3×0.0× | 0.3×+0.2× | 0.1×— | —— | |
| Liquidity | |||||
| Current ratio | 10×+2.7× | 7.3×-10.5× | 17.8×+4.5× | 13.3×-3.9× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Net debt / EBITDA | -2.9×+1.8× | -4.7×— | —— | —— | |
| Per Share | |||||
| Book value per share | $40.72+28.0% | $31.82+13.4% | $28.06+37.0% | $20.49-23.4% | |
| Valuation | |||||
| Market capitalization | $7.15B+58.7% | $4.51B+28.9% | $3.49B+71.3% | $2.04B+17.1% | |
| Price / earnings | 34.9×-15.6× | 50.5×-269× | 319.7×— | —— | |
| Price / sales | 18.4×+2.9× | 15.5×-53.4× | 68.9×— | —— | |
| Price / book | 5.9×+1.1× | 4.8×+0.3× | 4.5×+0.6× | 3.9×+1.0× | |
| EV / EBITDA | 39.9×-18.3× | 58.2×— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Krystal Biotech, Inc.'s ratios come from?
- Every ratio is computed from Krystal Biotech, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
